Register for our free email digests:
Latest From David Wallace
Bio-Thera Ventures Outside China With European Bevacizumab Filing
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
EU Pharma Strategy Will Remove Barriers And Bolster Competition
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Pfizer Confirms EU Pegfilgrastim Launch Plans
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Pfizer Picks Up EU Pegfilgrastim Approval
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
Alvotech Targets Chinese Biosimilars With Yangtze River Deal
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.
Insud’s Xiromed Rivals Taytulla In US
Xiromed has announced the introduction of the first generic rival to the Taytulla contraceptive in the US. The launch of Gemmily represents the latest new product for the Insud subsidiary following a busy year.